imatinib synthon 100 mg film - coated tablets
synthon bv - 100 mg film - coated tablets
imatinib synthon 400 mg film - coated tablets
synthon bv - 400 mg film - coated tablets
imatinib bioorganics 100 mg film - coated tablets
bioorganics bv - 100 mg film - coated tablets
imatinib bioorganics 400 mg film - coated tablets
bioorganics bv - 400 mg film - coated tablets
imatinib glenmark loomg film - coated tablet
glenmark pharmaceuticals s.r.o., - loomg film - coated tablet
imatinib glenmark 400mg film - coated tablet
glenmark pharmaceuticals s.r.o., - 400mg film - coated tablet
yervoy
bristol-myers squibb pharma eeig - Ипилимумаб - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - Антинеопластични средства - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4. yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 и 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.
nicalcimag solutio pro injectionibus
ВЕТПРОМ АД - borogluconate на калций; магнезий глюконат; калций glicerophosphate; Глюкоза - инжекционен разтвор - 100 mg/ml; 60 mg/ml; 50 mg/ml; 50 mg/ml - агнета, говеда, кози, коне, котки, кучета, овце, прасета, свине, телета, ярета